 LEXINGTON, Mass., July 7, 2021 PRNewswire -- Curis, Inc. NASDAQ: CRIS, a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 259,550 shares of Curis common stock to fifteen new employees, with a grant date of July 1, 2021 the Q3 2021 Inducement Grants. 